Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks

Abstract

Secukinumab is a recombinant, fully human monoclonal anti-IL-17A antibody approved to treat moderate-to-severe psoriasis and psoriatic arthritis. Its effectiveness and safety have been confirmed, but a gradual increase in the secukinumab dosing interval has not been investigated. To assess the feasibility, efficacy, and safety of gradually increasing the secukinumab dosing interval; the interval duration was determined by changes in the Psoriasis Area and Severity Index scores. Patients with moderate-to-severe plaque psoriasis received secukinumab 300 mg subcutaneously at baseline and weeks 0, 1, 2, and 3. At week 4, the improvement from baseline PASI guided the next injection time until week 36. In total, 83 patients were recruited. PASI 75 was achieved by 80%, 96%, and 95% of patients at weeks 4, 12, and 36, respectively. PASI 90 was achieved by 54%, 95%, and 84% of patients at weeks 4, 12, and 36, respectively. PASI 100 was achieved by 28%, 89%, and 68% of patients at weeks 4, 12, and 36, respectively. The average PASI score (1.05 ± 1.83) was significantly lower at week 36 than at baseline. Most patients reached PASI 75 at week 36 in our modified study. This study may provide information for future biotherapies.

Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice

“…Meanwhile, higher clinical improvements were reported in the modified therapy study at week 24 (96%/86%/76% for PASI 75/90/100, respectively). 9 In the real-world study including 66 Chinese patients with uninterrupted treatment of 300 mg secukinumab for 52 weeks, PASI 75 rate (92.7%) at week 52 was similar with our study, while PASI 90/100 rates (63.4%, 22%, respectively) were lower. 8 The real-world evidence of these studies and our findings demonstrate the prominent effectiveness of the secukinumab in the Chinese population.…”

“…Concerning effectiveness at week 24, Jing Zhang et al 6 reported higher responses of 100%/100%/67% for PASI 75/90/100 respectively. Meanwhile, higher clinical improvements were reported in the modified therapy study at week 24 (96%/86%/76% for PASI 75/90/100, respectively) 9 . In the real‐world study including 66 Chinese patients with uninterrupted treatment of 300 mg secukinumab for 52 weeks, PASI 75 rate (92.7%) at week 52 was similar with our study, while PASI 90/100 rates (63.4%, 22%, respectively) were lower 8 .…”

“…And most of these studies had small sample sizes and/or follow‐up periods of less than 12 months. PASI 75/90/100 responses with 300 mg secukinumab obtained at week 12 in our study were similar with two of previous reports (87.5–89% for PASI 75, 67–68.8% for PASI 90 and 33–43.8% for PASI 100, respectively), 6,7 higher than that of Yu Wang et al 8 (57.6% for PASI 90 and 10.6% for PASI 100, respectively) and lower than that of a modified therapy study with gradually increasing the dosing interval of secukinumab (95% for PASI 75, 88% for PASI 90 and 76% for PASI 100, respectively) 9 . Concerning effectiveness at week 24, Jing Zhang et al 6 reported higher responses of 100%/100%/67% for PASI 75/90/100 respectively.…”

“…for PASI 100, respectively). 9 Concerning effectiveness at week 24, Jing Zhang et al 6 reported higher responses of 100%/100%/67% for PASI 75/90/100 respectively. Meanwhile, higher clinical improvements were reported in the modified therapy study at week 24 (96%/86%/76% for PASI 75/90/100, respectively).…”